College of American pathologists' laboratory standards for next-generation sequencing clinical tests

Nazneen Aziz, Qin Zhao, Lynn Bry, Denise K. Driscoll, Birgit Funke, Jane S. Gibson, Wayne W. Grody, Madhuri R. Hegde, Gerald A. Hoeltge, Debra G B Leonard, Jason D. Merker, Rakesh Nagarajan, Linda A. Palicki, Ryan S. Robetorye, Iris Schrijver, Karen E. Weck, Karl V. Voelkerding

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

Context.-The higher throughput and lower per-base cost of next-generation sequencing (NGS) as compared to Sanger sequencing has led to its rapid adoption in clinical testing. The number of laboratories offering NGS-based tests has also grown considerably in the past few years, despite the fact that specific Clinical Laboratory Improvement Amendments of 1988/College of American Pathologists (CAP) laboratory standards had not yet been developed to regulate this technology. Objective.-To develop a checklist for clinical testing using NGS technology that sets standards for the analytic wet bench process and for bioinformatics or "dry bench" analyses. As NGS-based clinical tests are new to diagnostic testing and are of much greater complexity than traditional Sanger sequencing-based tests, there is an urgent need to develop new regulatory standards for laboratories offering these tests. Design.-To develop the necessary regulatory framework for NGS and to facilitate appropriate adoption of this technology for clinical testing, CAP formed a committee in 2011, the NGS Work Group, to deliberate upon the contents to be included in the checklist. Results.-A total of 18 laboratory accreditation checklist requirements for the analytic wet bench process and bioinformatics analysis processes have been included within CAP's molecular pathology checklist (MOL). Conclusions.-This report describes the important issues considered by the CAP committee during the development of the new checklist requirements, which address documentation, validation, quality assurance, confirmatory testing, exception logs, monitoring of upgrades, variant interpretation and reporting, incidental findings, data storage, version traceability, and data transfer confidentiality.

Original languageEnglish (US)
Pages (from-to)481-493
Number of pages13
JournalArchives of Pathology and Laboratory Medicine
Volume139
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Checklist
Computational Biology
Technology
Incidental Findings
Molecular Pathology
Accreditation
Information Storage and Retrieval
Confidentiality
Documentation
Pathologists
Costs and Cost Analysis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Aziz, N., Zhao, Q., Bry, L., Driscoll, D. K., Funke, B., Gibson, J. S., ... Voelkerding, K. V. (2015). College of American pathologists' laboratory standards for next-generation sequencing clinical tests. Archives of Pathology and Laboratory Medicine, 139(4), 481-493. https://doi.org/10.5858/arpa.2014-0250-CP

College of American pathologists' laboratory standards for next-generation sequencing clinical tests. / Aziz, Nazneen; Zhao, Qin; Bry, Lynn; Driscoll, Denise K.; Funke, Birgit; Gibson, Jane S.; Grody, Wayne W.; Hegde, Madhuri R.; Hoeltge, Gerald A.; Leonard, Debra G B; Merker, Jason D.; Nagarajan, Rakesh; Palicki, Linda A.; Robetorye, Ryan S.; Schrijver, Iris; Weck, Karen E.; Voelkerding, Karl V.

In: Archives of Pathology and Laboratory Medicine, Vol. 139, No. 4, 01.04.2015, p. 481-493.

Research output: Contribution to journalArticle

Aziz, N, Zhao, Q, Bry, L, Driscoll, DK, Funke, B, Gibson, JS, Grody, WW, Hegde, MR, Hoeltge, GA, Leonard, DGB, Merker, JD, Nagarajan, R, Palicki, LA, Robetorye, RS, Schrijver, I, Weck, KE & Voelkerding, KV 2015, 'College of American pathologists' laboratory standards for next-generation sequencing clinical tests', Archives of Pathology and Laboratory Medicine, vol. 139, no. 4, pp. 481-493. https://doi.org/10.5858/arpa.2014-0250-CP
Aziz, Nazneen ; Zhao, Qin ; Bry, Lynn ; Driscoll, Denise K. ; Funke, Birgit ; Gibson, Jane S. ; Grody, Wayne W. ; Hegde, Madhuri R. ; Hoeltge, Gerald A. ; Leonard, Debra G B ; Merker, Jason D. ; Nagarajan, Rakesh ; Palicki, Linda A. ; Robetorye, Ryan S. ; Schrijver, Iris ; Weck, Karen E. ; Voelkerding, Karl V. / College of American pathologists' laboratory standards for next-generation sequencing clinical tests. In: Archives of Pathology and Laboratory Medicine. 2015 ; Vol. 139, No. 4. pp. 481-493.
@article{73e6ea77df4b469cbb4472bbf74b5bfb,
title = "College of American pathologists' laboratory standards for next-generation sequencing clinical tests",
abstract = "Context.-The higher throughput and lower per-base cost of next-generation sequencing (NGS) as compared to Sanger sequencing has led to its rapid adoption in clinical testing. The number of laboratories offering NGS-based tests has also grown considerably in the past few years, despite the fact that specific Clinical Laboratory Improvement Amendments of 1988/College of American Pathologists (CAP) laboratory standards had not yet been developed to regulate this technology. Objective.-To develop a checklist for clinical testing using NGS technology that sets standards for the analytic wet bench process and for bioinformatics or {"}dry bench{"} analyses. As NGS-based clinical tests are new to diagnostic testing and are of much greater complexity than traditional Sanger sequencing-based tests, there is an urgent need to develop new regulatory standards for laboratories offering these tests. Design.-To develop the necessary regulatory framework for NGS and to facilitate appropriate adoption of this technology for clinical testing, CAP formed a committee in 2011, the NGS Work Group, to deliberate upon the contents to be included in the checklist. Results.-A total of 18 laboratory accreditation checklist requirements for the analytic wet bench process and bioinformatics analysis processes have been included within CAP's molecular pathology checklist (MOL). Conclusions.-This report describes the important issues considered by the CAP committee during the development of the new checklist requirements, which address documentation, validation, quality assurance, confirmatory testing, exception logs, monitoring of upgrades, variant interpretation and reporting, incidental findings, data storage, version traceability, and data transfer confidentiality.",
author = "Nazneen Aziz and Qin Zhao and Lynn Bry and Driscoll, {Denise K.} and Birgit Funke and Gibson, {Jane S.} and Grody, {Wayne W.} and Hegde, {Madhuri R.} and Hoeltge, {Gerald A.} and Leonard, {Debra G B} and Merker, {Jason D.} and Rakesh Nagarajan and Palicki, {Linda A.} and Robetorye, {Ryan S.} and Iris Schrijver and Weck, {Karen E.} and Voelkerding, {Karl V.}",
year = "2015",
month = "4",
day = "1",
doi = "10.5858/arpa.2014-0250-CP",
language = "English (US)",
volume = "139",
pages = "481--493",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "4",

}

TY - JOUR

T1 - College of American pathologists' laboratory standards for next-generation sequencing clinical tests

AU - Aziz, Nazneen

AU - Zhao, Qin

AU - Bry, Lynn

AU - Driscoll, Denise K.

AU - Funke, Birgit

AU - Gibson, Jane S.

AU - Grody, Wayne W.

AU - Hegde, Madhuri R.

AU - Hoeltge, Gerald A.

AU - Leonard, Debra G B

AU - Merker, Jason D.

AU - Nagarajan, Rakesh

AU - Palicki, Linda A.

AU - Robetorye, Ryan S.

AU - Schrijver, Iris

AU - Weck, Karen E.

AU - Voelkerding, Karl V.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Context.-The higher throughput and lower per-base cost of next-generation sequencing (NGS) as compared to Sanger sequencing has led to its rapid adoption in clinical testing. The number of laboratories offering NGS-based tests has also grown considerably in the past few years, despite the fact that specific Clinical Laboratory Improvement Amendments of 1988/College of American Pathologists (CAP) laboratory standards had not yet been developed to regulate this technology. Objective.-To develop a checklist for clinical testing using NGS technology that sets standards for the analytic wet bench process and for bioinformatics or "dry bench" analyses. As NGS-based clinical tests are new to diagnostic testing and are of much greater complexity than traditional Sanger sequencing-based tests, there is an urgent need to develop new regulatory standards for laboratories offering these tests. Design.-To develop the necessary regulatory framework for NGS and to facilitate appropriate adoption of this technology for clinical testing, CAP formed a committee in 2011, the NGS Work Group, to deliberate upon the contents to be included in the checklist. Results.-A total of 18 laboratory accreditation checklist requirements for the analytic wet bench process and bioinformatics analysis processes have been included within CAP's molecular pathology checklist (MOL). Conclusions.-This report describes the important issues considered by the CAP committee during the development of the new checklist requirements, which address documentation, validation, quality assurance, confirmatory testing, exception logs, monitoring of upgrades, variant interpretation and reporting, incidental findings, data storage, version traceability, and data transfer confidentiality.

AB - Context.-The higher throughput and lower per-base cost of next-generation sequencing (NGS) as compared to Sanger sequencing has led to its rapid adoption in clinical testing. The number of laboratories offering NGS-based tests has also grown considerably in the past few years, despite the fact that specific Clinical Laboratory Improvement Amendments of 1988/College of American Pathologists (CAP) laboratory standards had not yet been developed to regulate this technology. Objective.-To develop a checklist for clinical testing using NGS technology that sets standards for the analytic wet bench process and for bioinformatics or "dry bench" analyses. As NGS-based clinical tests are new to diagnostic testing and are of much greater complexity than traditional Sanger sequencing-based tests, there is an urgent need to develop new regulatory standards for laboratories offering these tests. Design.-To develop the necessary regulatory framework for NGS and to facilitate appropriate adoption of this technology for clinical testing, CAP formed a committee in 2011, the NGS Work Group, to deliberate upon the contents to be included in the checklist. Results.-A total of 18 laboratory accreditation checklist requirements for the analytic wet bench process and bioinformatics analysis processes have been included within CAP's molecular pathology checklist (MOL). Conclusions.-This report describes the important issues considered by the CAP committee during the development of the new checklist requirements, which address documentation, validation, quality assurance, confirmatory testing, exception logs, monitoring of upgrades, variant interpretation and reporting, incidental findings, data storage, version traceability, and data transfer confidentiality.

UR - http://www.scopus.com/inward/record.url?scp=84926314484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926314484&partnerID=8YFLogxK

U2 - 10.5858/arpa.2014-0250-CP

DO - 10.5858/arpa.2014-0250-CP

M3 - Article

C2 - 25152313

AN - SCOPUS:84926314484

VL - 139

SP - 481

EP - 493

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 4

ER -